Coverage
-
March 03, 2017
A proposed class of Geron Corp. investors have sought approval in California federal court for a $6.25 million settlement regarding claims that the company improperly touted a cancer drug before the U.S. Food and Drug Administration halted a clinical trial over liver toxicity concerns.
2 other articles on this case.
View all »